ProEthic Pharmaceuticals
Quick facts
Phase 3 pipeline
- PRO-513 · Diabetes
PRO-513 is a small molecule that targets the SGLT2 receptor.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: